Shree Ganesh Remedies Ltd Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Revenue growth is expected driven by increasing CRAMS (Contract Research and Manufacturing Services) projects, with trial quantities being supplied and ramp-up over multiple quarters.
- Peak volumes for CRAMS projects are anticipated 1.5 to 2 years down the line, indicating gradual scale-up.
- New blocks (9,10,11) at Ankleshwar planned but will be commissioned based on confirmed projects; gross block addition estimated at Rs. 50-80 crores.
- Dahej site expansion is planned for commercial-scale production once supply contracts are signed; construction expected to take 15-18 months after groundwork.
- European market demand has been dampened recently but expected to stabilize with increased inquiries from multiple geographies including Europe, Japan, and USA.
- Specialty chemicals and fine chemicals segments are showing promise with new inquiries and potential supplier upgrades.
- Long-term projects indicate stable revenue streams 2-3 years ahead.
- Overall margin guidance is 24-28% EBITDA, with higher margins in early CRAMS phases balancing out over time.
See what Shree Ganesh Remedies Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript from the Q2FY25 earnings call of Shree Ganesh Remedies Limited does not mention any current or planned fundraising through debt or equity.
- No specific comments were made about raising capital for ongoing or future projects.
- Capex plans for expansion (blocks 9, 10, 11 at Ankleshwar and new blocks at Dahej) are contingent on project approvals and customer contracts but no financing details were discussed.
- The company is focusing on phased project developments, backed by existing resources and project-specific investments rather than broad fundraising.
- Management emphasizes organic growth and capacity expansion based on customer demand without indicating external equity or debt issuance.
See what Shree Ganesh Remedies Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- Blocks 9, 10, and 11 at Ankleshwar will be commissioned and designed only when specific projects or chemistry requirements arise; typical Capex per block ranges between ₹10-20 crore, totaling ₹50-80 crore for the three blocks.
- Block 7 at Dahej is being finalized; construction usually takes 15-18 months post-approval.
- Dahej site is planned for large-scale, dedicated customer projects with major Capex starting 1.5 to 2 years from now after signing supply contracts.
- Current capacity expansions at Ankleshwar and ongoing efforts aim to support scale-up and sample submissions before major Dahej investments.
- The company employs a project-driven Capex approach, building capacity aligned with customer demand and technology.
- Block 8 has started commercial operations from Q1 FY25 and is expected to contribute meaningfully soon.
- Innovation efforts include backward integration and technology improvements to maintain margins and production efficiency.
Track Shree Ganesh Remedies Ltd — get its next earnings analysis in your feed
Margin guidance
Category 3- Growth expected to continue driven by strategic focus on product mix optimization and profitability enhancement (Page 4).
- Commercial supply for CRAMS projects ramping up over multiple quarters; peak volumes expected 1.5 to 2 years down the line (Pages 13-15).
- New blocks (9, 10, 11) and Dahej site expansions planned, contingent on project contracts, indicating capacity for future scale (Pages 13-14).
- EBITDA margins anticipated to normalize in the 24-28% range over the medium term; peak margin of 30%+ seen recently considered aberration due to initial CRAMS projects (Page 11).
- Revenue contribution from CRAMS projects expected to increase gradually but cautiously disclosed due to competitive reasons (Page 15).
- Backward integration efforts aimed at maintaining healthy margins amid volume-driven pricing pressure (Page 7).
- Overall, a steady revenue and margin growth trajectory is anticipated over 3-5 years with ongoing project commercialization and capacity expansion.
Order book
- Currently engaged in multiple CRAMS projects with some commercialized, including one started in Q4 of last year.
- Trial quantities for ongoing CRAMS projects expected around Q2 of next financial year.
- Major revenue and volume ramp-up from these projects anticipated 1.5 to 2 years down the line.
- Customer is conducting market studies to clarify peak volume; clearer visibility expected by Q4 FY25.
- Additional CRAMS projects are in pipeline, with sample approvals and R&D ongoing.
- No specific orderbook numbers disclosed due to competitive reasons and NDAs.
- Blocks 9, 10, and 11 expansions planned post-project confirmation; gross block investment estimated between Rs. 50-80 crores.
- Dahej site expansion contingent upon signed supply contracts for high-volume projects; commercial production expected after 1.5-2 years of sample approvals and construction.
How does Shree Ganesh Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Shree Ganesh Remedies Ltd rank in Pharmaceuticals & Biotechnology?
Compare Shree Ganesh Remedies Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…